A blister seems simple, but it can signal anything from a fracture to a life-threatening autoimmune attack, so here’s why ...

Patients with BP often use combinations of cardiovascular and antihypertensive drugs, but the risk linked to combinations does not exceed that linked to individual agents, according to a study.

Dupixent shows potential as a treatment for atopic dermatitis, alopecia and vitiligo, targeting shared immune pathways for ...

Biotech company Regeneron (NASDAQ:REGN) reported revenue ahead of Wall Street’s expectations in Q2 CY2025, with sales up 3.6% ...

Bullous pemphigoid is a rare autoimmune disease that causes painful chronic blisters and welts. it typically strikes elderly people who already have one or more diseases or are in poor health.

Dublin, Aug. 03, 2023 (GLOBE NEWSWIRE) -- The "Bullous pemphigoid - Pipeline Insight, 2023" clinical trials has been added to ResearchAndMarkets.com's offering.This "Bullous pemphigoid - Pipeline ...

The causes of bullous pemphigoid, which typically develops at age 70 and older, are not fully understood. There is evidence that in some people, it may be triggered by medications.

Pronounced “BULL-us PEM-fih-goyd” (with bullous being the medical term for a large blister), Bullous Pemphigoid is a rare, autoimmune, chronic skin disorder that causes large, fluid-fil… ...

The mean Bullous Pemphigoid Disease Area Index (BPDAI) decreased from 32 on day 1 to 19.6 on day 42. A BPDAI reduction of at least 8 points was recorded in seven of the nine patients, while three ...

Throughout the study period, 9304 patients were prescribed DPP4Is, and bullous pemphigoid developed in 8. Of those, 6 had a non-inflammatory form, and tests were negative for the antibody in 5.

The new data join an emerging literature linking the increased incidence of bullous pemphigoid in recent years with certain medications, and specifically, DPP-4 inhibitors, a class of type 2 ...

DUBLIN--(BUSINESS WIRE)--The "Bullous pemphigoid - Pipeline Insight, 2023" clinical trials has been added to ResearchAndMarkets.com's offering. The "Bullous Pemphigoid - Pipeline Insight, 2023 ...